We assessed hepatitis E virus (HEV) seroprevalence in patients with hepatic disorders as well as in human immunodeficiency virus (HIV)-infected patients and emphasised the issue of possible non-specific anti-HEV seroresponse and need for combining diagnostic methods for hepatitis E diagnosis. Over a two-year period, from March 2011 to February 2013, we determined anti-HEV immunoglobulin M (IgM) and IgG by enzyme immunoassays (EIA; Mikrogen, Germany) in 504 hepatitis patients negative for acute viral hepatitis A-C. Furthermore, 88 samples from randomly selected consecutive HIV-infected patients were also analysed. All EIA reactive samples were additionally tested by line immunoblot assays (LIA; Mikrogen, Germany). HEV nested reverse transcription polymerase chain reaction (RT-PCR) was carried out in 14 anti-HEV IgM LIA-positive patients. Anti-HEV IgM or IgG were detected in 16.9 % of patients by EIA and confirmed by LIA in 10.7 % [95 % confidence interval (CI) 8.3-13.7 %] of hepatitis patients. HEV RNA was detected in five patients. The agreement between EIA and LIA assessed by Cohen's kappa was 0.47 (95 % CI 0.55-0.75) for IgM and 0.83 (95 % CI 0.78-0.93) for IgG. Anti-HEV IgM and IgG seroprevalence in HIVinfected patients was 1.1 %, respectively. Our findings show a rather high HEV seroprevalence in patients with elevated liver enzymes in comparison to HIV-infected patients. Discordant findings by different methods stress the need to combine complementary methods and use a two-tier approach with prudent interpretation of reactive serological results for hepatitis E diagnosis.
Introduction
Hepatitis E infection is an emerging disease displaying hyperendemic outbreaks in developing countries and, yet, seems to be underestimated in industrialised regions. The cause of hepatitis E is a small non-enveloped RNA virus with four genotypes recognised in humans [1] . The hepatitis E virus (HEV) genome contains short non-coding regions and three discontinuous and partially overlapping open reading frames (ORF) for viral non-structural proteins (ORF1), viral capsid protein (ORF2) and proteins with still unclear functions from ORF3 [2, 3] . In developing regions, outbreaks are generally caused by human-specific genotypes 1 and 2, which are recognised as travel-associated HEV infections in developed countries. Genotypes 3 and 4 are considered to be causes of endemic infections with zoonotic potential, since they were isolated not only from humans but also from different mammalian species and marine animals [4] [5] [6] [7] [8] [9] [10] . HEV is acquired through the faecal-oral route, although sources of HEV frequently stay unrecognised [4] [5] [6] [7] [8] [9] [10] [11] [12] . Hepatitis E clinical presentation in healthy individuals is usually mild and self-limiting, and patients may not even seek medical attention [4, 5] . In contrary, in severely immunosuppressed patients, chronic HEV infection could be a cause of persistent alanine aminotransferase (ALT) elevation. So, HEV persistence may be a potential risk of disease progression also in human immunodeficiency virus (HIV)-infected patients [13] [14] [15] [16] [17] . HEV infection needs to be considered as a possible cause of unexplained increase in liver enzymes when common viral causes of hepatitis are excluded.
The diagnosis of HEV infection is based on the serological determination of anti-HEV immunoglobulin M (IgM) and IgG antibodies and/or nucleic acid-based testing [5, [18] [19] [20] . Viraemia is limited to the acute phase of illness, and both anti-HEV IgM and IgG are generally detectable at the onset of disease. Anti-HEV IgM declines rapidly and, 3-6 months after the occurrence of the first symptoms, are undetectable, while a rise in IgG antibody titre is observed [21] . Acute hepatitis E is defined when anti-HEV IgM and IgG in serum or HEV RNA is documented. The finding of anti-HEV IgM when IgG and HEV RNA remain undetectable could not be considered as an acute hepatitis E infection. Serological HEV diagnostic is not standardised. Diagnostic performances and results differ in specificity and sensitivity of the utilised commercially available assays. Serological findings depend on the principle of enzyme immunoassays (EIA; indirect or μ-capture method) and the used antigen selections and conformations [5, 14, [18] [19] [20] [21] [22] [23] [24] . Although HEV is antigenically consistent and only one serotype has been identified, recombinant antigens used for antibody testing are not optimised. Newgeneration assays based on HEV ORF2 genotypes 1 and 3 (Wantai/Fortress, Mikrogen) represent a significant step towards establishing serological standards [20] [21] [22] [23] .
Hepatitis E has been a notifiable disease in Croatia since 1994. Until 2012, only a few travel-associated HEV cases per year were registered [25, 26] . Even so, HEV has been detected in domestic swine and wild boars [8, 27] , resulting in a possibility of viral spread to humans [28] . Therefore, accurate and quick diagnosis is needed in order to distinguish HEV infection from other causes of acute viral hepatitis. The aim of this study was to assess HEV seroprevalence in patients with hepatic disorders as well as HIV-infected patients and to evaluate the serological diagnosis of hepatitis E using EIA followed by immunoblot assays (LIA) and reverse transcription polymerase chain reaction (RT-PCR).
Patients and methods
Over a 2-year period, from March 2011 until February 2013, sera from 504 patients (age range 16 to 81 years) with elevated liver enzymes [ALT and aspartate aminotransferase (AST) >2× upper limit of normal (ULN)] were serologically tested at the University Hospital for Infectious Diseases in Zagreb for viral hepatitis E. Furthermore, 88 sera samples from randomly retrospectively selected consecutive HIV-infected patients (age range 20 to 80 years) were also tested for the presence of anti-HEV IgM and IgG. Moreover, the CD4 cell count was available for 85 of the HIV-infected patients included in the study, with a median of 279 cells/mm 3 For confirmation of acute and recent HEV infection, a nested RT-PCR was carried out in 14 patients by a protocol described by van der Poel et al. [7] . HEV RT-PCR was conducted on sera with positive anti-HEV IgM. A fragment of 287 bp within the metal transferase gene region of ORF1 was the amplification target. RNA was isolated by the QIAamp® Viral RNA Kit (Qiagen, Germany), according to the manufacturer's instructions. The reverse transcription was carried out using the GoScript Reverse Transcription System for RT-PCR (Promega, USA) in a GeneAmp PCR System 9700 machine (Applied Biosystems, USA). Thirty-five PCR cycles were conducted by the use of two pairs of primers (nested PCR). Electrophoresis was done in a 1.5 % agarose gel. All samples with a band of 287 bp were considered as HEV-positive.
The agreement between EIA and LIA for IgM and IgG anti-HEV assays was quantified with Cohen's kappa coefficient. Statistical analysis was performed using Statistica 8.0 (StatSoft).
Results
Anti-HEV reactive antibodies determined by EIA were found in 85 of the 504 (16.9 %) patients with hepatic disorders. Of the 85 anti-HEV EIA-positive patients, 42 (49.4 %) were males, with a median age of 48 years. Anti-HEV IgM and IgG were reactive by EIA in 46 (54.1 %) and 51 (60.0 %) of the 85 patients, respectively (Fig. 1a) . Anti-HEV antibodies were confirmed by LIA in 54 of the 85 (63.5 %) EIA-reactive patients. Anti-HEV IgM and IgG were positive by LIA in 16 of 46 (34.8 %) and 44 of 51 (86.3 %) EIA-reactive patients, respectively. Unconfirmed EIA-reactive anti-HEV IgM or IgG antibodies comprised 31 (6.2 %) patients. Anti-HEV antibodies were confirmed by LIA in 10.7 % of all hepatitis HIV-negative patients.
Even though 11 (12.5 %) HIV-infected patients displayed EIA-positive anti-HEV IgM, only in one patient (1.1 %) was the positive EIA result positive also by LIA. However, this patient had no clinical signs or elevated liver enzymes, so a possible false-positive LIA finding could not be excluded. Of the 88 HIV-infected patients, one (1.1 %) had confirmed anti-HEV IgG antibodies as a sign of past infection (Fig. 1b) .
Different serological IgM and IgG profiles were found by EIA in comparison to LIA ( HEV RT-PCR was conducted in patients with positive anti-HEV IgM, and HEV RNA was found in five of 14 (35.7 %) tested patients.
To determine the influence of other hepatotropic viruses, except for viral hepatitis A-C, patients were also tested for EBV and CMV. Among patients with anti-HEVantibodies, 42 (49.4 %) had serological signs of past HAV, HBV or HCV infection. Anti-HAV was the most commonly detected ( Table 2) .
From 16 patients with positive and five patients with borderline LIA anti-HEV IgM, hepatitis was caused by CMV in 4 (19.0 %) and EBV in 1 (4.8 %). One patient with EIA-reactive anti-HEV IgM that was not confirmed by LIA had an acute EBV infection. Among eight HIV-infected patients with EIApositive anti-HEV IgM, acute CMV infection was found in 3 (37.5 %), EBV in 1 (12.5 %) and 1 (12.5 %) HIV-infected patient had syphilis.
Specific antibodies against different HEV antigens are displayed by LIA, of which the most commonly represented were anti-HEV IgM for the O2N antigen (47.8 %) and IgG for the O2C antigen (86.3 %) (Fig. 2) . The reactivity to the HEV O3 antigen was high for both antibody classes, while it was low against the O2M antigen. The differentiation between HEV genotypes 1 and 3 according to the bands reactivity might be only assumed, but it was not reliable. Further validation is needed.
Discussion
Even though Croatia is considered a country of low HEV incidence with sporadic, mostly imported HEV cases [25] , the average seroprevalence in patients with non-specific elevation of liver enzymes and negative for acute viral hepatitis A-C assessed by EIA followed by LIA was 10.7 %. HEV seroprevalence gained by EIA only was even higher (16.9 %). The HEV IgG seroprevalence in HIV-infected patients was lower (1.1 %) than in patients with hepatic disorders, and might presume the seroprevalence of the adult population in general, while HIV-infected patients according to the literature are not at increased risk of acquiring HEV infection [5] . Our results show discrepancies related to the used methods and reinforce previous reports on difficulties in HEV diagnostic. for anti-HEV IgG was very good but was only moderate for IgM.
The data on HEV seroprevalence gained by different testing approaches are demanding for analysis, although, in general, our results may be comparable with others [10, 13, 20, 22, [29] [30] [31] [32] [33] . There is a high probability that our patients were HEV-infected in Croatia, since there is no recognition of their recent travel to endemic regions and all HEV RNA determined were of genotype 3 that was documented in swine, although a direct connection with viral transmission cannot be defined. Therefore, the sources of infection remain unrecognised [8, 27] . According to EIA anti-HEV IgM, even 46 patients could be considered as acute HEV cases but in only eight of them was recent HEV infection confirmed by RT-PCR or the increase of IgG titre in a convalescent serum. All patients with positive HEV RNA showed a high anti-HEV IgM titre and had detectable IgG when they requested medical attention. Only one HEV RNA-positive patient had anti-HEV IgM without IgG; however, this patient seroconverted to IgG very quickly. The findings support previous reports that anti-HEV IgM detected in only one serum sample is not sufficient for establishing HEV diagnosis [5, 20, 24, 29, [34] [35] [36] [37] .
Reactive anti-HEV IgM may be the result of polyclonal B cell activation by EBVor other infections which can induce B cells [24, [34] [35] [36] [37] . False-positive IgM anti-HEV due to acute EBV, CMVand syphilis were documented also in our patients. The overdiagnosis of acute hepatitis E due to possible falsepositive results should not be neglected and needs to be recognised and reduced. One possible solution may be the use of a two-tier approach combining anti-HEV IgM and IgG screening by EIA with additional testing by LIA. The detection of HEV RNA is always recommended, especially in recent illness [18] .
The limitations of the study need to be noted. We used LIA and EIA based on the same antigens from the same manufacturer (Mikrogen). However, similar two-tier testing approaches are used for borreliae and HCV to show specific reactions against separate antigens and to exclude unspecific EIA reactions. According to published data for patients with positive HEV RNA, the specificity and sensitivity of newer serological tests show very good performances [5, [20] [21] [22] [23] , but in routine clinical practice, patients with different simultaneous diagnoses may gain unspecific ambiguous anti-HEV results, so the seroprevalence rates may differ significantly 
23 (54.8 %) 3 (7.1 %) 3 (7.1 %) 1 (2.4 %) 12 (28.6 %) according to used diagnostic protocols. Low positive predictive values, even for high-sensitive EIA due to low prevalence, imposes the need to check all positive and borderline results [20] . This supports the importance of combining at least two assays to assess the result. A two-step testing approach with anti-HEV IgM and IgG EIA and LIA, which has a positive impact regarding on the specificity, could be recommended. A further solution could also be combining two EIA with high sensitivity and specificity [14, 21, 22] . LIA was criticised for its low sensitivity [23] , even though it is not intended for screening purposes (high cost, labour complexity) but for confirmation. According to our clinical practice, patients with unconfirmed LIA anti-HEV IgM were unlikely to be HEV-infected; some of them had other hepatitis infections that emphasise the importance of differential diagnosis. In our study, positive anti-HEV antibodies were found in 49.4 % of patients with a past HAV, HBVor HCV infection, and the clinical impact of HEV in these patients is yet to be defined, since co-infection with HEV could pose a severe health risk among persons with pre-existing chronic liver disease [13, 14, 17, 32] .
From our limited experience, immunocompetent patients with acute hepatitis E when seeking medical attention mostly have detectable antibodies by EIA and LIA. Viraemia seems to be documented as long as IgM exceeds the IgG titre. Acute HEV infection with only anti-HEV IgM findings and without HEV RNA seems to be rarely possible. When HEV RNA decreases to undetectable levels, anti-HEV IgM decline as well, while anti-HEV IgG titres increase [21] . In the subacute phase of infection, HEV RNA may already be undetectable and the antibody kinetic needs to be monitored in follow-up testing. Unfortunately, a consecutive serum sample is often unavailable. We managed to collect paired sera from only 2.4 % of tested patients. Furthermore, the diagnosis of HEV infection solely by serological testing may result in falsenegative findings when HEV is recently acquired. Therefore, diagnosis in such cases needs to be assessed by the further testing of a new serum and/or with HEV RT-PCR.
Whether serotyping is even possible via different specific antibodies against genotypes 1 or 3 by LIA, and if these antibodies are cross-protective, remains to be elucidated. The current data set by Pas et al. [21] shows cross-reactivity between known genotypes 1 and 3 sera. We found high reactivity against the N-terminal (O2N) and C-terminal parts (O2C) of the capsid protein for IgM and IgG, respectively, similar to the specific LIA bands findings in Germany [2, 33] . Further follow-up studies during HEV disease are needed in order to reveal the expression of different antigens in HEV pathways and the role of specific antibodies.
In conclusion, our findings show a rather high HEV seroprevalence in patients with hepatic disorders compared with HIV-infected patients in Croatia. Discordant findings by different methods (16.9 % and 10.7 % anti-HEV by EIA and LIA, respectively) stress the need to combine complementary methods and use a two-tier approach with prudent interpretation of reactive serological results for hepatitis E diagnosis. Combining EIA as a screening method with LIA or other sensitive and highly specific EIA for additional evaluation, as well as a follow-up anti-HEV IgG to document possible seroconversion or IgG titre increase and also HEV RT-PCR, could be recommended for definite diagnosis because falsepositive IgM and IgG findings should not be neglected. 
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